Rhabdomyosarcoma (RM) is a malignant tumor originating from somatic tissue, particularly striated muscle. It is the most common form of soft tissue sarcoma in children and adolescents, although it can also occur in adults. Rhabdomyosarcoma is classified into several morphologic subtypes, including alveolar, embryonal, capacitive, and anaplastic forms, which can occur in various anatomical sites, such as the head, neck, genitourinary system, and other tissues. The prognosis for patients with rhabdomyosarcoma varies depending on age, stage of disease, and tumor differentiation, but is generally highly aggressive and requires a multidisciplinary approach to treatment.
History of the disease and interesting historical facts
Rhabdomyosarcoma was first described in medical literature in the mid-19th century. In 1854, German physician Rudolf Virchow described malignant tumors associated with muscle tissue. In the 1920s, researchers began to classify different types of sarcomas, among which rhabdomyosarcoma was singled out. Over the following decades, significant progress was made in understanding the biology of the tumor, its molecular markers, and mechanisms of metastasis. In the 1970s, the first chemotherapy regimens were developed, which significantly improved patient outcomes, increasing survival.
Epidemiology
Rhabdomyosarcoma accounts for approximately 3% of all childhood cancers and is most commonly diagnosed in children under 5 years of age. Epidemiological data show that the incidence among boys exceeds that among girls, which is due to differences in sex predisposition. According to various studies, the incidence is between 4 and 5 cases per 1 million children under 14 years of age. More than 60% cases are reported in younger children, with peak incidence in children aged 2 to 6 years. It is important to note that key geographic differences in prevalence have not been established, and cases are seen worldwide.
Genetic predisposition to this disease
According to modern research, genetic factors play a significant role in the development of alveolar rathematomyosarcoma. In particular, patients with hereditary syndromes such as Li-Fraumeni syndrome and Neufeld syndrome have an increased risk of developing this disease. At the morphological level, important markers are mutations in the TP53, PAX3, PAX7 and FGFR4 genes, which are present in many cases of alveolar rathematomyosarcoma. There are studies confirming the presence of chromosomal abnormalities, especially deletions and translocations, which makes them potential targets for molecular targeted therapy.
Risk factors for the development of this disease
There are various risk factors that may contribute to the development of rhabdomyosarcoma. In general, the following groups can be distinguished:
- Genetic predisposition, including hereditary diseases and syndromes.
- Exposure to chemical carcinogens (eg, benzene, pesticides), which may also increase the risk of developing tumors.
- Physical factors such as radiation, particularly radiation therapy, previously given for other malignancies.
- Inflammatory diseases and injuries of soft tissues.
- Individual predisposition, for example, the occurrence of previous benign soft tissue neoplasms.
Diagnosis of this disease
Diagnosis of rhabdomyosarcoma is often a complex process and involves several steps:
- The main symptoms may include the presence of a tumor, pain, swelling, and functional impairment in the corresponding area.
- Laboratory tests, including a complete blood count and biochemistry, may reveal signs of inflammation, but there are no specific markers.
- Radiological examinations, including ultrasound, MRI and CT, help determine the size of the tumor and its location, as well as identify the presence of metastases.
- Other diagnostic methods, such as immunohistochemistry and molecular genetic studies, are essential for clarifying the morphological type and pathogenesis.
- Differential diagnosis is important to exclude other malignant diseases such as blue cell sarcoma, fibrosarcoma, etc.
Treatment
Treatment of rhabdomyosarcoma requires a multi-tiered approach and may include:
- General treatment, which includes both surgery and adjuvant chemotherapy.
- Pharmacological treatment, including various chemotherapy regimens based on drugs such as vincristine, actinomycin D and doxorubicin.
- Surgical treatment including exegetical resection of the tumor with the aim of achieving radical removal.
- Other treatments, such as radiation therapy, may be used both before and after surgery to shrink the tumor and control recurrence.
List of medications used to treat this disease
The main drugs used in the treatment of rabotomyosarcoma include:
- Vincristine
- Docorubicin
- Actinomycin D
- Cyclophosphamide
- etoposide
- Gemcitabine
Disease monitoring
Patient monitoring after treatment for rabotomyosarcoma includes control stages over several years. The prognosis depends on the stage of the disease, the response to treatment, and complete removal of the tumor. Complications may include relapse, metastasis, and side effects from chemotherapy and radiotherapy that affect the quality of life of patients. Regular examinations using radiological methods and laboratory tests play a key role in the timely diagnosis of relapse.
Age-related features of the disease
Rhabdomyosarcoma can present differently depending on age group. Infants and young children often have a large number of soft tissue tumors, while adolescents may have a more aggressive course of the disease and a high probability of metastasis. Adult patients tend to have a worse prognosis, and their tumors are more likely to undergo sporadic mutations.
Questions and Answers
- What is rabotomyosarcoma? Rhabdomyosarcoma is a malignant tumor originating from striated muscle, most commonly found in children.
- What are the main symptoms of rhabdomyosarcoma? The main symptoms include the presence of a tumor, pain, swelling and functional impairment in the affected area.
- What are the treatments for rhabdomyosarcoma? Treatment includes surgical removal of the tumor, chemotherapy and radiotherapy.
- What are the risk factors for developing rhabdomyosarcoma? Risk factors include genetic predisposition, exposure to carcinogens, and previous injuries.
- What is the survival prognosis for patients with rhabdomyosarcoma? The prognosis depends on the stage of the disease, the size of the tumor and the degree of differentiation, but treatment is effective in most cases if detected early.
